Relevance evaluation between serum zinc -alpha 2-glycoprotein levels in mid pregnancy and gestational diabetes

doi:10.3877/cma.j.issn.2095-9605.2020.03.004

Abstract

Abstract:

Objective

To investigate the expression level of serum ZAG protein in patients with gestational diabetes mellitus and the predictive effect of ZAG protein and early Pregnancy index on GDM.

Methods

42 patients with gestational diabetes mellitus who were examined in the third affiliated Hospital of Zhengzhou University from July 2018 to April 2019 were included in the GDM group, and 42 healthy pregnant women were treated as control group in the same period, and 24-28 weeks of OGTT spatiotemporal abdominal serum were collected. The serum ZAG levels of the two groups were detected by enzyme-linked immunosorbent method (ELISA) and compared, and the baseline data and early biochemical indexes of pregnancy were collected and analyzed retrospectively. Using a paired T-test, Mann-Whitney U test group comparison, using logistic regression to analyze the link between indicators and disease.

Results

The expression level of serum ZAG protein in the GDM group was lower than that in control group, pre-pregnancy BMI, early pregnancy fasting blood glucose(FPG) and triglycerides (TG) were higher in the GDM group than in the control group, and all the difference were statistically significant (P<0.05), and logistic regression analysis showed that FPG ,age ,were Increases the incidence of GDM; ZAG is an independent protective factor for GDM. ROC curve analysis indicators showed ZAG is the predictive abilities (P<0.05) for GDM.

Conclusions

The expression level of ZAG in the serum of the GDM group is significantly lower than that in the control group, and ZAG may be involved in the occurrence and development of GDM, which is expected to be used as a new high specificity index for the clinical diagnosis of GDM.

Key words: Gestational diabetes mellitus, Zinc-α2-Glycoprotein, lipid metabolism

Hongli Su, Guixia Chen, Li Zhang, Dongmei Xu. Relevance evaluation between serum zinc -alpha 2-glycoprotein levels in mid pregnancy and gestational diabetes[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2020, 06(03): 159-164.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfpydxbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9605.2020.03.004

https://zhfpydxbdzzz.cma-cmc.com.cn/EN/Y2020/V06/I03/159

Figures/Tables 7

References 20

[1]	Burgi W, Schmid K. Preparation and properties of Zn-alpha 2-glycoprotein of normal human plasma[J]. J Biol Chem, 1961, 236: 1066-1074.
[2]	Bing C, Bao Y, Jenkins J, et al. Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia[J]. Proc Natl Acad Sci USA, 2004, 101(8): 2500-2505.
[3]	Zhu HJ, Ding HH, Deng JY, et al. Inhibition of preadipocyte differentiation and adipogenesis by zinc-alpha2-glycoprotein treatment in 3T3-L1 cells[J]. J Diabetes Investig, 2013, 4(3): 252-260. URL
[4]	Ryden M, Agustsson T, Andersson J, et al. Adipose zinc-alpha2-glycoprotein is a catabolic marker in cancer and noncancerous states[J]. J Intern Med, 2012, 271(4): 414-420. URL
[5]	Yang M, Liu R, Li S, et al. Zinc-alpha2-glycoprotein is associated with insulin resistance in humans and is regulated by hyperglycemia, hyperinsulinemia, or liraglutide administration: cross-sectional and interventional studies in normal subjects, insulin-resistant subjects, and subjects with newly diagnosed diabetes[J]. Diabetes Care, 2013, 36(5): 1074-1082. URL
[6]	Gennaro G, Palla G, Battini L, et al. The role of adipokines in the pathogenesis of gestational diabetes mellitus[J]. Gynecol Endocrinol, 2019, 35(9): 737-751.
[7]	Kowalska K, Olejnik A. Cranberries (Oxycoccus quadripetalus) inhibit pro-inflammatory cytokine and chemokine expression in 3T3-L1 adipocytes[J]. Food Chem, 2016, 196: 1137-1143.
[8]	Marrades MP, Martinez JA, Moreno-Aliaga MJ. ZAG, a lipid mobilizing adipokine, is downregulated in human obesity[J]. J Physiol Biochem, 2008, 64(1): 61-66. URL
[9]	Hassan MI, Waheed A, Yadav S, et al. Zinc alpha 2-glycoprotein: a multidisciplinary protein[J]. Mol Cancer Res, 2008, 6(6): 892-906.
[10]	Bing C, Bao Y, Jenkins J, et al. Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia[J]. Proc Natl Acad Sci U S A, 2004, 101(8): 2500-2505.
[11]	Tian M, Liang Z, Liu R, et al. Effects of sitagliptin on circulating zinc-alpha2-glycoprotein levels in newly diagnosed type 2 diabetes patients: a randomized trial[J]. Eur J Endocrinol, 2016, 174(2): 147-155.
[12]	Zhang AY, Grogan JS, Mahon KL, et al. A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer[J]. Ann Oncol, 2017, 28(8): 1903-1909.
[13]	Wargent ET, O'Dowd JF, Zaibi MS, et al. Contrasts between the effects of zinc-alpha2-glycoprotein, a putative beta3/2-adrenoceptor agonist and the beta3/2-adrenoceptor agonist BRL35135 in C57Bl/6 (ob/ob) mice[J]. J Endocrinol, 2013, 216(2): 157-168.
[14]	Russell ST, Tisdale MJ. Role of beta-adrenergic receptors in the anti-obesity and anti-diabetic effects of zinc-alpha2-glycoprotien (ZAG)[J]. Biochim Biophys Acta, 2012, 1821(4): 590-599.
[15]	Gong FY, Zhang SJ, Deng JY, et al. Zinc-alpha2-glycoprotein is involved in regulation of body weight through inhibition of lipogenic enzymes in adipose tissue[J]. Int J Obes (Lond), 2009, 33(9): 1023-1030.
[16]	Ceperuelo-Mallafre V, Ejarque M, Duran X, et al. Zinc-alpha2-Glycoprotein Modulates AKT-Dependent Insulin Signaling in Human Adipocytes by Activation of the PP2A Phosphatase[J]. PLoS One, 2015, 10(6): e129644.
[17]	Russell ST, Tisdale MJ. Studies on the anti-obesity activity of zinc-alpha2-glycoprotein in the rat[J]. Int J Obes (Lond), 2011, 35(5): 658-665.
[18]	王媛媛，张龑．妊娠期糖尿病早期预测的研究进展[J]．国际妇产科学杂志，2016，43(03)：287-290．
[19]	Wang C, Zhu W, Wei Y, et al. The Predictive Effects of Early Pregnancy Lipid Profiles and Fasting Glucose on the Risk of Gestational Diabetes Mellitus Stratified by Body Mass Index[J]. J Diabetes Res, 2016, 2016: 3013567.
[20]	Li P, Yin Y, Lin S, et al. Utility of Pregestational Body Mass Index and Initial Fasting Plasma Glucose in Predicting Gestational Diabetes Mellitus[J]. Am J Med Sci, 2016, 351(4): 420-425.

?	GDM组（n=42）	对照组（n=42）	t/Z	P值
年龄（岁）	31.00±4.22	29.02 ± 3.69	1.447	0.152
孕前BMI（kg/m²）	22.58±3.12	20.99 ± 2.47	2.674	0.011^*
孕次	2（1,2）	2（1.00, 2.50）	-0.073	0.942
产次	0（0, 1）	0（0, 1）	-0.447	0.655

?	GDM组（n=42）	对照组（n=42）	t/Z	P值
年龄（岁）	31.00±4.22	29.02 ± 3.69	1.447	0.152
孕前BMI（kg/m²）	22.58±3.12	20.99 ± 2.47	2.674	0.011^*
孕次	2（1,2）	2（1.00, 2.50）	-0.073	0.942
产次	0（0, 1）	0（0, 1）	-0.447	0.655

?	GDM组（n=42）	对照组（n=42）	t/Z	P值
FPG（mmol/L）	4.83（4.59,5.16）	4.68（4.62,4.68）	-2.821	0.005^*
TG（mmol/L）	1.44±0.69	1.14±0.42	-2.458	0.018^*
TC（mmol/L）	4.45±0.74	4.57±0.67	0.732	0.468
HDL-C（mmol/L）	1.54±0.25	1.57±0.28	0.481	0.633
LDL-C（mmol/L）	2.46±0.53	2.48±0.46	0.221	0.827

?	GDM组（n=42）	对照组（n=42）	t/Z	P值
FPG（mmol/L）	4.83（4.59,5.16）	4.68（4.62,4.68）	-2.821	0.005^*
TG（mmol/L）	1.44±0.69	1.14±0.42	-2.458	0.018^*
TC（mmol/L）	4.45±0.74	4.57±0.67	0.732	0.468
HDL-C（mmol/L）	1.54±0.25	1.57±0.28	0.481	0.633
LDL-C（mmol/L）	2.46±0.53	2.48±0.46	0.221	0.827

?	GDM组（n=42）	对照组（n=42）	t/Z	P值
ZAG（μg/mL）	35.40（27.96,44.68）	45.34（33.11,63.99）	-3.240	<0.001^*
OGTT（0h）（mmol/L）	5.13 ± 0.49	4.52 ± 0.32	-6.048	<0.001^**
OGTT（1h）（mmol/L）	9.34 ± 1.77	6.75 ± 1.23	-7.362	<0.001^**
OGTT（2h）（mmol/L）	8.09 ± 1.38	6.23 ± 0.98	-7.352	<0.001^**

Please choose a citation manager

Content to export